FindTrial
Sign In

Serum TSH level as a predictor of thyroid cancer in patients with newly diagnosed thyroid nodule.

Serum TSH level : A competent tool for assessing risk of malignancy of thyroid nodules with indeterminate cytology in euthyroid patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/10/037654
Enrollment
300
Registered
2021-10-28
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C73- Malignant neoplasm of thyroid gland

Interventions

None listed

Sponsors

Amrita Institute of Medical Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All euthyroid patients who underwent thyroid surgery for newly diagnosed thyroid nodules with FNAC reported as indeterminate cytology (Bethesda III) were included in our study.

Exclusion criteria

Exclusion criteria: Patients, other than Bethesda class III or those already diagnosed with thyroid malignancy were excluded from the study. Other exclusion criteria were patients on thyroid hormone supplementation and Serum TSH level not within the euthyroid range.

Design outcomes

Primary

MeasureTime frame
Mean Serum TSH levelTimepoint: at baseline—

Secondary

MeasureTime frame
Quartile based Serum TSH levelTimepoint: at baseline—

Countries

India

Contacts

Public ContactRiju Ramachandran

Amrita Institute of Medical sciences

rijurmenon@gmail.com9447041973

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026